DGIdb - NEVIRAPINE Drug Record

NEVIRAPINE chembl:CHEMBL57 Approved

Alternate Names:

BIRG-0587
NEVIRAPINE ANHYDROUS
VIRAMUNE
NSC-641530
VIRAMUNE XR
NEVIRAPINE
2',3'-E)(1,4)DIAZEPIN-6-ONE
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B:2',3'-E)(1,4)DIAZEPIN-6-ONE
NVP
NEV
rxcui:53654
chemidplus:129618-40-2
pubchem.compound:4463
drugbank:00238
chembl:CHEMBL57

Drug Info:

(1 More Sources)

Publications:

Weiss J et al., 2007, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors., Drug Metab Dispos
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Lehr T et al., 2011, Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine., Pharmacogenet Genomics
Chantarangsu S et al., 2011, Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash., Clin Infect Dis
Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics
Haas DW et al., 2006, Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration., Clin Infect Dis
Ritchie MD et al., 2006, Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity., Clin Infect Dis
Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother
Gozalo C et al., 2011, Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial., Basic Clin Pharmacol Toxicol
Mahungu T et al., 2009, Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population., HIV Med
Petit et al., 2003, Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study., J. Lipid Res.
Borgiani P et al., 2014, HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique., Eur J Clin Pharmacol
Ciccacci C et al., 2017, Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility., Eur J Clin Pharmacol
Olagunju A et al., 2016, Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study., Pharmacogenet Genomics
Ciccacci C et al., 2013, Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study., Eur J Clin Pharmacol
Heil SG et al., 2012, Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals., Ther Drug Monit
Yuan J et al., 2011, Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent., AIDS
Chen J et al., 2010, CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients., Ther Drug Monit
Rotger M et al., 2005, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients., Pharmacogenet Genomics
Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
Faucette et al., 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers., J. Pharmacol. Exp. Ther.
Petit et al., 2004, Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors., Eur. J. Clin. Invest.
Liptrott NJ et al., 2012, Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS., Pharmacogenet Genomics

NEVIRAPINE CCHCR1

Interaction Score: 5.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21810746

Sources:
PharmGKB
NEVIRAPINE TCF19

Interaction Score: 5.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21810746

Sources:
PharmGKB
NEVIRAPINE POLR3G

Interaction Score: 5.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21810746

Sources:
PharmGKB
NEVIRAPINE CYCSP5

Interaction Score: 4.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28689274 24322967

Sources:
PharmGKB
NEVIRAPINE TRAF3IP2

Interaction Score: 2.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
NEVIRAPINE HCP5

Interaction Score: 1.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24322967

Sources:
PharmGKB
NEVIRAPINE ABCC10

Interaction Score: 1.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22082652

Sources:
PharmGKB
NEVIRAPINE ADIPOQ

Interaction Score: 1.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15305892

Sources:
NCI
NEVIRAPINE CYP2B6

Interaction Score: 0.9

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28689274 27195527 23774940 22354160 21860339 21824325 21505298 20625352 20017669 19228205 15864119 11470993 17638512 17041008

Sources:
NCI PharmGKB
NEVIRAPINE APOB

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12869587

Sources:
NCI
NEVIRAPINE HLA-DQB1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
NEVIRAPINE ABCC3

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17172311

Sources:
DTC
NEVIRAPINE ABCC1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17172311

Sources:
DTC
NEVIRAPINE CYP3A5

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21824325 20017669 19228205

Sources:
PharmGKB
NEVIRAPINE ABCC2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17172311

Sources:
DTC
NEVIRAPINE ABCG2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21189339

Sources:
DTC
NEVIRAPINE ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20017669 16912957 16912956 21189339

Sources:
DTC PharmGKB
NEVIRAPINE NR1I2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
NEVIRAPINE CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21860339 22931300

Sources:
DTC PharmGKB
NEVIRAPINE CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
NEVIRAPINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
NEVIRAPINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
NEVIRAPINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB

NCI: NEVIRAPINE

Version: 14-September-2017

Alternate Names:

C29277 NCI drug code

Drug Info:

Publications:

Faucette et al., 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers., J. Pharmacol. Exp. Ther.

Petit et al., 2004, Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors., Eur. J. Clin. Invest.

Petit et al., 2003, Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study., J. Lipid Res.

DTC: NEVIRAPINE

Version: 02-September-2020

Alternate Names:

CHEMBL57 ChEMBL Drug ID

Drug Info:

Publications:

Weiss J et al., 2007, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors., Drug Metab Dispos

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother

PharmGKB: nevirapine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics

Haas DW et al., 2006, Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration., Clin Infect Dis

Ritchie MD et al., 2006, Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity., Clin Infect Dis

TTD: Nevirapine
- Version: 2020.06.01
Alternate Names:

D0O2EM TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL57
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

NEVIRAPINE Drug Record

NEVIRAPINE chembl:CHEMBL57 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21810746

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21810746

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21810746

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28689274 24322967

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24322967

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22082652

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15305892

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28689274 27195527 23774940 22354160 21860339 21824325 21505298 20625352 20017669 19228205 15864119 11470993 17638512 17041008

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12869587

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17172311

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17172311

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21824325 20017669 19228205

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17172311

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21189339

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20017669 16912957 16912956 21189339

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21860339 22931300

Interaction Types & Directionality:

n/a

PMIDs:
21810746

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21810746

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21810746

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28689274 24322967

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24322967

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22082652

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15305892

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
28689274 27195527 23774940 22354160 21860339 21824325 21505298 20625352 20017669 19228205 15864119 11470993 17638512 17041008

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12869587

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17172311

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17172311

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21824325 20017669 19228205

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17172311

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21189339

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
20017669 16912957 16912956 21189339

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21860339 22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC PharmGKB

Alternate Names:

C29277 NCI drug code

Alternate Names:

CHEMBL57 ChEMBL Drug ID

Alternate Names:

D0O2EM TTD Drug ID